531 related articles for article (PubMed ID: 31115593)
1. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.
Niedeggen C; Singer S; Groth M; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
Ann Hematol; 2019 Jul; 98(7):1547-1559. PubMed ID: 31115593
[TBL] [Abstract][Full Text] [Related]
2. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.
Groth M; Singer S; Niedeggen C; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
Ann Hematol; 2017 Feb; 96(2):171-181. PubMed ID: 27837250
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.
Weitz I; Meyers G; Lamy T; Cahn JY; Uranga MT; García Vela JA; Sanz MA; Severino B; Kelly RJ; Hillmen P; Hill A
Intern Med J; 2013 Mar; 43(3):298-307. PubMed ID: 22909078
[TBL] [Abstract][Full Text] [Related]
4. Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH).
Weisshaar K; Ewald H; Halter J; Gerull S; Schönfeld S; Senft Y; Martinez M; Leuppi-Taegtmeyer A; Khanna N; Maier B; Risitano A; Peffault de Latour R; Tichelli A; Passweg J; Drexler B
Orphanet J Rare Dis; 2020 Sep; 15(1):249. PubMed ID: 32943103
[TBL] [Abstract][Full Text] [Related]
5. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).
Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E
J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105
[TBL] [Abstract][Full Text] [Related]
6. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
[TBL] [Abstract][Full Text] [Related]
7. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
[TBL] [Abstract][Full Text] [Related]
8. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.
Escalante CP; Chisolm S; Song J; Richardson M; Salkeld E; Aoki E; Garcia-Manero G
Cancer Med; 2019 Feb; 8(2):543-553. PubMed ID: 30632713
[TBL] [Abstract][Full Text] [Related]
9. No impact of Asian ethnicity on EORTC QLQ-C30 scores: Group differences and differential item functioning in paroxysmal nocturnal hemoglobinuria.
Schwartz CE; Stark RB; Borowiec K; Myren KJ
Health Qual Life Outcomes; 2021 Sep; 19(1):228. PubMed ID: 34583705
[TBL] [Abstract][Full Text] [Related]
10. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
[TBL] [Abstract][Full Text] [Related]
11. Analysis of abnormal clones by the fluorescent aerolysin method in paroxysmal nocturnal haemoglobinuria and other marrow disorders.
Agarwal R; Chapple P; Brown M; Szer J; Juneja S
Int J Lab Hematol; 2015 Feb; 37(1):14-21. PubMed ID: 24702736
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study.
Kulagin A; Lisukov I; Ivanova M; Golubovskaya I; Kruchkova I; Bondarenko S; Vavilov V; Stancheva N; Babenko E; Sipol A; Pronkina N; Kozlov V; Afanasyev B
Br J Haematol; 2014 Feb; 164(4):546-54. PubMed ID: 24261566
[TBL] [Abstract][Full Text] [Related]
13. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.
Flechtner H; Rüffer JU; Henry-Amar M; Mellink WA; Sieber M; Fermé C; Eghbali H; Josting A; Diehl V
Ann Oncol; 1998; 9 Suppl 5():S147-54. PubMed ID: 9926255
[TBL] [Abstract][Full Text] [Related]
14. Development of clinical paroxysmal nocturnal haemoglobinuria in children with aplastic anaemia.
Narita A; Muramatsu H; Okuno Y; Sekiya Y; Suzuki K; Hamada M; Kataoka S; Ichikawa D; Taniguchi R; Murakami N; Kojima D; Nishikawa E; Kawashima N; Nishio N; Hama A; Takahashi Y; Kojima S
Br J Haematol; 2017 Sep; 178(6):954-958. PubMed ID: 28643364
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
16. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26.
Holzner B; Efficace F; Basso U; Johnson CD; Aaronson NK; Arraras JI; Smith AB; Chow E; Oberguggenberger AS; Bottomley A; Steiner H; Incrocci L; Giesinger JM
Qual Life Res; 2013 Mar; 22(2):369-78. PubMed ID: 22407356
[TBL] [Abstract][Full Text] [Related]
17. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ;
Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338
[TBL] [Abstract][Full Text] [Related]
18. Psychometric properties of the EORTC QLQ-C30 in Uganda.
Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
20. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
